Company Analysis
Sign in

Traws Pharma, Inc. (TRAW)

Nasdaq: TRAW · Pharmaceutical Preparations · Newtown, PA · filing with the SEC since 2003
Full chart Alerts Compare
Grade4.3
◀ Past 2.8● Present 2.4▶ Future 7.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

22 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Traws Pharma, Inc.’s names, not what it holds today.

Patents granted
22
22 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and none in 2023
Applications published
28
1 of them in 2025
Names they are printed under
4
a former name, its own name, a subsidiary
By yearGrantedApplications published
'09'10'11'12'13'15'16'17'18'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
ONCONOVA THERAPEUTICS, INC. a former name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in GB)
21 granted
21 published
ONCONOVA THERAPEUTICS, INC. a former name
named as the applicant on its applications, in US
0 granted
6 published
TRAWS PHARMA, INC. its own name
US, as the owner printed on each patent
1 granted
0 published
Trawsfynydd Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 3, 202412,156,856Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailabilityPharmaceuticalsTRAWS PHARMA, INC.
Jul 12, 202211,382,877Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailabilityPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Mar 3, 202010,576,050Methods and compositions for treatment of cancerPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Oct 16, 201810,098,862Formulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfonesPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Jul 25, 20179,713,597Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfonePharmaceuticalsONCONOVA THERAPEUTICS, INC.
Jun 23, 20159,060,967Stable aqueous formulation of (E)-4-carboxystyryl-4-chlorobenzyl sulfonePharmaceuticalsONCONOVA THERAPEUTICS, INC.
Jun 2, 20159,044,427Compositions and methods for prevention and treatment of woundsPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Jul 2, 20138,476,320Formulations for parenteral administration of amino-substituted (E)-2, 6-dialkoxystyryl 4-substituted benzylsulfonesPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Dec 4, 20128,324,190Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfonesPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Sep 25, 20128,273,787Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditionsPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 11, 20252025/0376464Compounds for treatment a coronavirus infectionOrganic fine chemistryTrawsfynydd Therapeutics, Inc.
Nov 14, 20242024/0374601METHODS AND COMPOSITIONS FOR TREATING CANCERPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Nov 14, 20242024/0374600METHODS AND COMPOSITIONS FOR TREATING CANCERPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Nov 7, 20242024/0366610METHODS AND COMPOSITIONS FOR TREATING CANCERPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Sep 12, 20242024/0299326METHODS AND COMPOSITIONS FOR TREATING CANCERPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Aug 15, 20242024/0269099METHODS AND COMPOSITIONS FOR TREATING CANCERPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Mar 9, 20232023/0070681FORMULATION OF (E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYLSULPHONE WITH ENHANCED STABILITY AND BIOAVAILABILITYPharmaceuticalsONCONOVA THERAPEUTICS, INC. · patent 12,156,856 granted from it
Jan 6, 20222022/00022938-CYCLOPENTYL-7-OXO-2-(4-PIPERAZIN-1-YL-PHENYLAMINO)-7, 8-DIHYDRO-PYRIDO [2,3-D]PYRIMIDINE-6-CARBONITRILE AND USES THEREOF IN TREATING PROLIFERATIVE DISORDERSPharmaceuticalsONCONOVA THERAPEUTICS, INC.
Jun 24, 20212021/0186902FORMULATION OF (E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYLSULPHONE WITH ENHANCED STABILITY AND BIOAVAILABILITYPharmaceuticalsONCONOVA THERAPEUTICS, INC. · patent 11,382,877 granted from it
Oct 18, 20182018/0296513FORMULATIONS WITH ENHANCED STABILITY AND BIOAVAILABILITY FOR ADMINISTANTION OF (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONESPharmaceuticalsONCONOVA THERAPEUTICS, INC. · patent 10,098,862 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton TRAW · research, not advice